Congress Park Capital LLC reduced its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 30.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 673,686 shares of the biotechnology company's stock after selling 290,904 shares during the quarter. Congress Park Capital LLC owned about 0.84% of CytomX Therapeutics worth $428,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of CTMX. Northern Trust Corp lifted its stake in CytomX Therapeutics by 16.0% during the 4th quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company's stock valued at $155,000 after acquiring an additional 20,746 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in CytomX Therapeutics by 1.5% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,547,215 shares of the biotechnology company's stock valued at $1,594,000 after acquiring an additional 23,139 shares during the period. Miller Financial Services LLC acquired a new stake in CytomX Therapeutics during the 4th quarter valued at approximately $26,000. Prudential Financial Inc. lifted its stake in CytomX Therapeutics by 76.2% during the 4th quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company's stock valued at $66,000 after acquiring an additional 27,800 shares during the period. Finally, Algert Global LLC acquired a new stake in CytomX Therapeutics during the 4th quarter valued at approximately $35,000. 67.77% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several brokerages have commented on CTMX. Wall Street Zen upgraded shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th. Wedbush restated an "outperform" rating and set a $6.00 price objective (up from $5.00) on shares of CytomX Therapeutics in a research note on Monday, May 12th. Piper Sandler lifted their price objective on shares of CytomX Therapeutics from $2.50 to $5.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. Finally, HC Wainwright raised shares of CytomX Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a report on Thursday, May 15th.
Check Out Our Latest Stock Report on CTMX
CytomX Therapeutics Stock Down 6.9%
Shares of NASDAQ:CTMX traded down $0.16 during trading on Monday, hitting $2.16. 2,400,647 shares of the stock traded hands, compared to its average volume of 2,189,220. The company has a market cap of $174.14 million, a price-to-earnings ratio of 4.50 and a beta of 2.09. The company has a fifty day moving average price of $1.77 and a two-hundred day moving average price of $1.14. CytomX Therapeutics, Inc. has a 52-week low of $0.40 and a 52-week high of $3.10.
CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $50.92 million during the quarter, compared to analyst estimates of $35.42 million. CytomX Therapeutics had a net margin of 28.22% and a negative return on equity of 553.71%. During the same period in the previous year, the firm earned $0.17 EPS. On average, equities research analysts predict that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.
CytomX Therapeutics Profile
(
Free Report)
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Recommended Stories

Before you consider CytomX Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.
While CytomX Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.